Intravenous immunoglobulin protects from experimental allergic bronchopulmonary aspergillosis via a sialylation-dependent mechanism

Eur J Immunol. 2019 Jan;49(1):195-198. doi: 10.1002/eji.201847774. Epub 2018 Oct 29.

Abstract

Intravenous immunoglobuin (IVIG) exerts protective effects in experimental allergic bronchopulmonary aspergillosis (ABPA) via a sialylation-dependent mechanism. The protection was associated with reduced recruitment of eosinophils, diminished goblet cell hyperplasia, suppressed Th2 and Th17 responses and reciprocally enhanced regulatory T cells and IL-10, and decreased IgE levels in the circulation.

Keywords: ABPA; Aspergillus fumigatus; IL-17F; IVIG; Tregs.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aspergillosis, Allergic Bronchopulmonary / therapy*
  • Cells, Cultured
  • Eosinophils / immunology*
  • Goblet Cells / immunology*
  • Humans
  • Immunoglobulin E / blood
  • Immunoglobulins, Intravenous / therapeutic use*
  • Interleukin-10 / metabolism
  • Mice
  • Mice, Inbred C57BL
  • N-Acetylneuraminic Acid / metabolism
  • T-Lymphocytes, Regulatory / immunology*
  • Th17 Cells / immunology*
  • Th2 Cells / immunology*

Substances

  • Immunoglobulins, Intravenous
  • Interleukin-10
  • Immunoglobulin E
  • N-Acetylneuraminic Acid